2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Young Adult
PAPER

3290 Strategic sequencing of immunotherapy in relapsed/refractory Ph-negative B-cell acute lymphoblastic leukemia: Integrating Italian real-world data from the Campus ALL network.

Antonio Curti Sr, MD, Sabina Chiaretti, MD2, Mario Delia3, Francesco Grimaldi, MD4, Federico Lussana, MD, PhD5, Lisa Argnani6, Robin Foà, MD7, Nicola Stefano Fracchiolla, MD8
1 Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
3 U.O.C. Ematologia con Trapianto, Azienda Ospedaliero-Universitaria-Consorziale Policlinico, Bari, Italy
4 Hematology Section, PO San Giuliano, ASL Napoli 1 Nord, Napoli, Italy
5 Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII, Bergamo, Italy, Department of Oncology and Hematology, Università degli Studi di Milano, Milan, Italy., Bergamo, Italy
6 Department of Medical and Surgical sciences (DIMEC), University of Bologna, Bologna, Italy
7 Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, “Sapienza” Università di Roma, Roma, Italy
8 Hematology, IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano, MILAN, Italy

Background. Relapsed or refractory (R/R) Philadelphia- B-cell acute lymphoblastic leukemia (Ph- B- ALL) has been associated with a poor outcome. Conventional salvage chemotherapy yields complete remission (CR) rates <40% and a median overall survival (OS) of less than 6 months. The therapeutic paradigm has changed with targeted immunotherapies: blinatumomab (blina), inotuzumab ozogamicin (InO), and CD19-directed CAR-T cells. These agents significantly improve CR and measurable residual disease (MRD) negativity, facilitating access to allogeneic hematopoietic stem cell transplant (allo-HSCT). The optimal sequencing of these therapies remains however undefined, and clinicians must balance disease burden, patients (pts) fitness, and treatment history.

Methods. To establish clinical recommendations on immunotherapy sequencing, a panel of expert hematologists integrated clinical trial evidence with real-world data from the Campus ALL National network. The survey collected retrospective data from 36 Italian centers (both CAR-T cell accredited and non-accredited) managing adult R/R Ph- B-ALL patients between January 2021 and December 2025. The analysis focused on treatment sequences, age-related treatment selection, previous transplant exposure, and organizational barriers affecting access to treatment.

Results. Treatment sequences were reported for 295 pts, including 78 CAR-T cells. The most frequent strategies were InO alone (57), blina alone (49), blina followed by HSCT (39), InO followed by HSCT (29), chemotherapy alone (23), CAR-T cells alone (13). More complex sequences including CAR-T cells were: CAR-T cells followed by HSCT (7), InO followed by CAR-T cells (23), InO followed by CAR-T cells and HSCT (11), InO followed by blina and CAR-T cells (1 with HSCT intensification; 1 without HSCT intensification), blina followed by CAR-T cells (5 with HSCT intensification; 7 without HSCT intensification), blina followed by InO and CAR-T cells (3 with HSCT intensification; 7 without HSCT intensification).

Age significantly influenced treatment selection: among pts receiving InO alone, 42.1% were aged >65 years, whereas CAR-T cell-based strategies were predominantly used in younger pts. In particular, 76.9% of CAR-T cells alone pts and 100% of CAR-T cells followed by HSCT pts, were aged ≤55 years.

CAR-T cell therapy was also frequently used as a salvage strategy after failing a prior HSCT, including, among the most frequent sequences, 7/20 pts treated with CAR-T cells (2 with HSCT intensification; 5 without HSCT intensification), 10/34 pts treated with InO followed by CAR-T cells (9 without HSCT intensification; 1 with HSCT intensification), and 7/12 pts treated with blina followed by CAR-T (3 with HSCT intensification; 4 without HSCT intensification). InO emerged as a cytoreductive bridge, particularly for high-burden disease, a setting in which blina is typically less effective and requires preventive debulking. With regard to accessibility to immunotherapy, the following items that require improvement emerged from the survey:

Referral of pts with advanced disease or clinical deterioration with consequent treatment ineligibility (reported in 14 cases across blina, InO, and CAR-T cells). Lack of caregiver support. Insufficient inpatient availability. Liver disease (for InO treatment). The 3-4 week "vein-to-vein" manufacturing interval for CAR-T cells and the possibility of disease progression.

Conclusions. Real-world data from the Campus ALL survey highlight the increasing integration of immunotherapies in the management of R/R Ph- B-ALL. Treatment selection and sequencing were strongly influenced by age, disease burden, prior transplantation, and access-related factors. For fit, transplant-eligible pts, the sequence InO followed by CAR-T cells and allo-HSCT represents an appealing clinical strategy that may contribute to achieve a rapid debulking, deep molecular remission, and long-term OS. InO provides an optimal bridge by reducing tumor burden in preparation for CAR-T cell therapy without exerting selective pressure on CD19 expression. Strategies of MRD driven post-CAR -T intensification with HSCT warrant future specifically tailored studies. To maintain and maximize the potential of these curative sequences, there is a continuous need to optimize hub-and-spoke referral networks, ensuring timely specialist evaluation to prevent disease progression or clinical complications that may preclude access to advanced immunotherapies.

Antonio Curti Sr, MD: AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Honoraria; AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Consultancy (Includes expert testimony)